The Global Gastroesophageal Reflux Disease Therapeutics Market is Predict to reach $5.6 Billion by 2028, at a CAGR of 2.2%

Gastroesophageal Reflux Disease Therapeutics Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Gastroesophageal Reflux Disease Therapeutics Market size is expected to reach $5.6 billion by 2028, rising at a market growth of 2.2% CAGR during the forecast period.

The Antacids segment is leading the Global Gastroesophageal Reflux Disease Therapeutics Market by Type in 2021 thereby, achieving a market value of $3 billion by 2028. This is because it is one of the most popular over-the-counter pharmaceuticals globally, and customers seeking treatment for acid reflux and heartburn spend billions of dollars on these. They treat GERD, heartburn, acid indigestion, hyperacidity, and upset stomach symptoms brought on by these conditions. The segment's expansion is also linked to the public's growing understanding of self-medication. Consumers prefer over-the-counter medications over professional medical services, which is further fueling the segment's growth.

The North America market dominated the Global Gastroesophageal Reflux Disease Therapeutics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $2.1 billion by 2028. The Europe market is exhibiting a CAGR of 1.8% during (2022 - 2028). Additionally, The Asia Pacific market would display a CAGR of 2.9% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/gastroesophageal-reflux-disease-therapeutics-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Global Gastroesophageal Reflux Disease Therapeutics Market Segmentation

By Type

• Antacids
• Proton Pump Inhibitors (PPIs)
• H2 Receptor Blockers
• Pro-kinetic Agents

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• AstraZeneca PLC
• Eisai Co., Ltd.
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Medigus Ltd.
• Sebela Pharmaceuticals
• Phathom Pharmaceuticals, Inc.
• Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

Unique Offerings from KBV Research

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

Related Reports:

North America Gastroesophageal Reflux Disease Therapeutics Market Future Scope & Opportunities 2022-2028

Europe Gastroesophageal Reflux Disease Therapeutics Market Size & Growth Forecast 2022-2028

Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Outlook to 2028

LAMEA Gastroesophageal Reflux Disease Therapeutics Market Growth, Trends & Forecasts 2022-2028